Novel natural inhibitors targeting KRAS G12C by computational study Jiang, Yuting; Chen, Wanting; Wang, Xinhui; More Jiang, Yuting; Chen, Wanting; Wang, Xinhui; Zhou, Baolin; Xie, Haoqun; Hou, Yuanyuan; Guo, Zhen; Yu, Bo; Zhong, Sheng; Su, Xing Less Anti-Cancer Drugs. 33(9):779-788, October 2022. Abstract Abstract Favorite PDF Permissions Buy
Design of novel quinoline derivatives as antibreast cancer using 3D-QSAR, molecular docking and pharmacokinetic investigation El Rhabori, Said; El Aissouq, Abdellah; Chtita, Samir; More El Rhabori, Said; El Aissouq, Abdellah; Chtita, Samir; Khalil, Fouad Less Anti-Cancer Drugs. 33(9):789-802, October 2022. Abstract Abstract Favorite PDF Permissions Buy
Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies Cortiula, Francesco; Pelizzari, Giacomo; Corvaja, Carla; More Cortiula, Francesco; Pelizzari, Giacomo; Corvaja, Carla; De Maglio, Giovanna; Fasola, Gianpiero Less Anti-Cancer Drugs. 33(9):960-962, October 2022. Abstract Abstract Favorite PDF Permissions Go to Full Text of this Article Open
Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report Li, Sixiang; Lin, Xinqing; Sun, Shiyong; More Li, Sixiang; Lin, Xinqing; Sun, Shiyong; Li, Shiyue; Zhou, Chengzhi Less Anti-Cancer Drugs. 33(9):963-965, October 2022. Abstract Abstract Favorite PDF Permissions Buy
